SNOA - オクルス・イノベイティブ・サイエンス (Sonoma Pharmaceuticals Inc.) オクルス・イノベイティブ・サイエンス

 SNOAのチャート


 SNOAの企業情報

symbol SNOA
会社名 Sonoma Pharmaceuticals Inc (オクルス・イノベイティブ・サイエンス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 ソノマ・ファーマシューティカルズ(Sonoma Pharmaceuticals Inc.)(旧名:Oculus Innovative Sciences Inc)は皮膚病気と先端ティッシュケア治療用のソリューションの開発・販売に従事する専門製薬会社である。同社の製品ポートフォリオはMicrocynとLipogrid等の技術に基づいた皮膚科学、動物の健康、高度なティッシュケア製品を含む。Microcynは小分子のオキシ塩素化合物を含む液体とゲルで構成される。同社の製品は感染症、かゆみ、痛み、瘢痕及び炎症反応の軽減に応用される。その製品は、米国及び国際的に販売される。  オクルス・イノベイティブ・サイエンスは、米国のヘルスケア企業。処方薬、市販製品を設計、生産、販売する。皮膚科、外科、傷や組織のケア、および動物の医療市場向けの製品を提供する。抗生物質の必要性を低減しつつ、感染症を治療し、治癒を促進するように設計されているMicrocynテクノロジ―と呼ばれる技術プラットフォ―ムを実用化する。   Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. The company's products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma's stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company'sproducts are sold either directly or via partners in 54 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Woodstock, Georgia, with manufacturing operations in Latin America. European marketing and sales are headquartered in Roermond, Netherlands.
本社所在地 1129 North McDowell Blvd. Petaluma CA 94954 USA
代表者氏名 James J. Schutz ジェームズ・J.シュッツ
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 707-283-0550
設立年月日 36251
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 225人
url www.oculusis.com
nasdaq_url https://www.nasdaq.com/symbol/snoa
adr_tso
EBITDA EBITDA(百万ドル) -13.85600
終値(lastsale) 1.72
時価総額(marketcap) 11106358.2
時価総額 時価総額(百万ドル) 11.10636
売上高 売上高(百万ドル) 17.19200
企業価値(EV) 企業価値(EV)(百万ドル) 3.89936
当期純利益 当期純利益(百万ドル) -14.27800
決算概要 決算概要 BRIEF: For the three months ended 30 June 2018 Sonoma Pharmaceuticals Inc revenues increased 14% to $4.4M. Net loss decreased 1% to $3.5M. Revenues reflect Product increase of 14% to $4.1M Service increase of 18% to $274K. Lower net loss reflects Other income (expense) net increase from $168K (expense) to $51K (income) Interest Income increase of 4% to $55K (income).

 SNOAのテクニカル分析


 SNOAのニュース

   Hypertrophic and Keloid Scar Treatment Market is expected to reach US$ 9,972.69 Mn by 2027 | Alliance Pharma plc; Mölnlycke HEALTH CARE AB.; Smith & Nephew; Newmedical Technology Inc.; Rejûvaskin; Sonoma Pharmaceuticals, Inc.; Suneva Medical; HRA Pharma  2021/07/19 13:56:04 OpenPR
According to our new research study on Hypertrophic and Keloid Scar Treatment Market Forecast to 2027 COVID-19 Impact and Global Analysis by Scar Type, Product Type, and End User, the hypertrophic and keloid scar treatment market was valued
   Sonoma Pharmaceuticals reports Q4 results  2021/07/15 09:25:55 Seeking Alpha
   Sonoma Pharmaceuticals Inc. Shares Close the Week 29.8% Higher - Weekly Wrap  2020/12/11 22:30:00 Kwhen Finance
Sonoma Pharmaceuticals Inc. shares closed the week 29.8% higher than it did at the end of last week. The stock is currently up 100.9% year-to-date, up 101.1% over the past 12 months, and up 53.7% over the past five years. This week, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 rose 0.0%. Trading Activity Shares traded as high as $15.19 and as low as $6.00 this week. Shares closed 1e+1% below its 52-week high and 1e+2% above its 52-week low. Trading volume this week was 95.5% lower than the 10-day average and 87.1% lower than the 30-day average. Beta, a measure of the stocks volatility relative to the overall market stands at 0.2. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. MACD, a trend-following momentum indicator, indicates an upward trend. The stock closed below its Bollinger band, indicating it may be oversold. The stock closed at 28.4% higher than its 5-day moving average, 25.9% higher than its 20-day moving average, and 14.0% higher than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's price-earnings ratio beats its average peer by -100.0% The company's performance over the last 1 year beats its average peer by -1195.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Sonoma Pharmaceuticals to Present at Upcoming Spring Virtual Investor Conferences  2021/03/04 22:03:00 Business Wire
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermatological conditions, today announced that CEO Amy Trombly and CFO Jerry Dvonch will present at the following upcoming virtual conferences. Event H.C. Wainwright Global Life Sciences Conference Date March 9-10, 2021
   Sonoma Pharmaceuticals Reports Third Quarter FY 2021 Financial Results  2021/02/16 22:30:00 Business Wire
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions today announced financial results for its third fiscal quarter and nine months ended December 31, 2020. “We continue to effectively execute our business plan of increasing revenue while reducing our expense
   Keloid Treatment Market to See Fabulous Rise by 2027 with Novartis AG, Sensus Healthcare, RXi Pharmaceuticals, Inc., Sonoma Pharmaceuticals, Inc. | FMI Report  2021/02/16 17:54:48 OpenPR
According to the latest market report published by FMI titled‘Keloid Treatment Market: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027),’the global keloid treatment market is estimated to be worth US$ 3,145.8 Mn by 2017 end, and is expected to expand
   BREAKING ALERT: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Sonoma Pharmaceuticals, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – SNOA - Stocks News Feed  2021/02/15 20:45:00 Stocks News Feed
NEW YORK, Feb. 15, 2021 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Sonoma… Read More »BREAKING ALERT: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Sonoma Pharmaceuticals, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – SNOA
   Sonoma Pharmaceuticals and Microderm Technologies Announce that Dermodacyn® Disinfecting Solution is Now Available in Hong Kong and Thailand  2021/01/28 21:30:00 Business Wire
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, disinfectant use and dermatological conditions, and Microderm Technologies Ltd. announce that Dermodacyn® disinfectant has received import clearance as a medical device for Thailand with the help from Microderm’s partner VetSynova Co.
   ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. – SNOA  2020/12/24 21:07:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public. On November 17, 2020, after market hours, Sonoma filed a Form 8-K with the U.S. Securities and Exchange Commission announcing that Sonoma’s “unaudited condensed consolidate
   Why Sonoma, Medicenna And Dare Bioscience Are Trading Higher Today  2020/12/18 17:13:40 Benzinga
Sonoma Pharmaceuticals (NASDAQ: SNOA ) shares are … Full story available on Benzinga.com
   Sonoma Pharmaceuticals Announces Partnership with Gabriel Science, LLC For Dental Markets  2020/12/17 21:10:00 Business Wire
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals and Gabriel Science enter into distribution agreement for the sale of HOCl-products into the dental markets.
   SNOA Stock: Sonoma Pharmaceuticals Heads up on Partnership News  2020/12/11 14:16:02 CNA Finance
SNOA stock is headed for the top in the market after announcing it has entered into a new partnership with Crown Laboratories.
   Sonoma Pharmaceuticals and Crown Laboratories Announce an Exclusive Partnership to Launch Microcyn® Technology-Based Anti-Itch Over-the-Counter Products  2020/12/10 21:10:00 Business Wire
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals and Crown Laboratories announce an exclusive partnership to launch Microcyn® Technology-based anti-itch OTC products.

 関連キーワード  (医薬品 米国株 オクルス・イノベイティブ・サイエンス SNOA Sonoma Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)